- On 30 July 2026, the FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulks list.
- Its stated reason: insufficient evidence of clinical need for outsourcing facilities to compound these from bulk substances.
- A public comment docket is open through 29 July 2026; a final determination comes after.
- It is a proposal, not a final rule — but it points toward a wind-down of large-scale GLP-1 compounding.
What the FDA actually proposed
The 503B bulks list governs which bulk drug substances FDA-registered outsourcing facilities may use to compound medications at scale. After reviewing nominations, the FDA said it did not identify sufficient evidence to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, basing the determination on patient safety and medical necessity. The agency opened a docket for public comment and will weigh submissions before deciding.
Why now
Compounded GLP-1s expanded during the 2022 shortages, when supply of branded products couldn't meet demand. Once the FDA declared those shortages resolved, the legal basis for large-scale compounding narrowed and wind-down enforcement deadlines followed. Safety has been the other driver: reporting on the proposal notes that by early 2025 the agency had logged hundreds of adverse-event reports tied to compounded versions, many involving incorrect self-dosing from multidose vials.
Reported adverse events — compounded GLP-1s (as of early 2025)
What it means for patients on compounded GLP-1s
The cost stakes are why this matters to so many people. During the shortage window, compounded options were widely available at roughly $150–$300/month versus $1,000+ for branded products before insurance — a gap that drove the cash-pay market.
Why cash-pay patients turned to compounding
Where transparency-focused providers fit
If compounding access narrows, sourcing transparency becomes more important, not less. Programs that name their 503A and 503B pharmacy partners and disclose their model give patients a clearer basis to ask informed questions. Among providers in our directory, NexLife discloses named pharmacy partners and flat-rate program pricing; as with any provider, confirm pricing, eligibility, and medication availability directly before enrolling.
FAQ
Is compounded GLP-1 illegal now?
What's the deadline to comment?
What's the difference between 503A and 503B?
Sources
- U.S. FDA — "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (press announcement, fda.gov).
- Pharmacy Times — analysis of the FDA proposal and adverse-event totals (July 2026).